JP2010520758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520758A5 JP2010520758A5 JP2009552983A JP2009552983A JP2010520758A5 JP 2010520758 A5 JP2010520758 A5 JP 2010520758A5 JP 2009552983 A JP2009552983 A JP 2009552983A JP 2009552983 A JP2009552983 A JP 2009552983A JP 2010520758 A5 JP2010520758 A5 JP 2010520758A5
- Authority
- JP
- Japan
- Prior art keywords
- reovirus
- nucleic acid
- residue
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000702263 Reovirus sp. Species 0.000 claims 69
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 150000007523 nucleic acids Chemical class 0.000 claims 38
- 230000004048 modification Effects 0.000 claims 35
- 238000012986 modification Methods 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 230000001965 increasing effect Effects 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 claims 4
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 claims 4
- 108700034660 Reovirus lambda3 Proteins 0.000 claims 4
- 230000006037 cell lysis Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000725641 Reovirus S4 Species 0.000 claims 2
- 108700018523 Reovirus mu2 Proteins 0.000 claims 2
- 108700023681 Reovirus sigma NS Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000004900 autophagic degradation Effects 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000008406 drug-drug interaction Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 230000007505 plaque formation Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 241000702244 Orthoreovirus Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89442507P | 2007-03-12 | 2007-03-12 | |
| US60/894,425 | 2007-03-12 | ||
| US98956807P | 2007-11-21 | 2007-11-21 | |
| US60/989,568 | 2007-11-21 | ||
| PCT/CA2008/000483 WO2008110004A1 (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010520758A JP2010520758A (ja) | 2010-06-17 |
| JP2010520758A5 true JP2010520758A5 (cg-RX-API-DMAC7.html) | 2011-04-28 |
| JP5577103B2 JP5577103B2 (ja) | 2014-08-20 |
Family
ID=39758956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552983A Active JP5577103B2 (ja) | 2007-03-12 | 2008-03-11 | 改変配列を有するレオウイルス |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7803385B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2132315B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5577103B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101647843B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103710359A (cg-RX-API-DMAC7.html) |
| AR (1) | AR066395A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008226291B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2678721C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2132315T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2548442T3 (cg-RX-API-DMAC7.html) |
| IL (4) | IL200353A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2009009598A (cg-RX-API-DMAC7.html) |
| SG (1) | SG191602A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200904979A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008110004A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200905951B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| EP2132315B1 (en) * | 2007-03-12 | 2015-07-15 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
| MX2010003556A (es) * | 2007-10-22 | 2010-04-21 | Oncolytics Biotech Inc | Regimen de tratamiento para trastornos proliferantes. |
| WO2009143610A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
| MX2010014555A (es) * | 2008-06-26 | 2011-04-27 | Ceva Sante Animale Sa | Reoviridae aviar unico. |
| FR2939807B1 (fr) * | 2008-12-11 | 2010-12-17 | Biomerieux Sa | Nouveau reovirus isole, procedes et kits de detection |
| US9395356B2 (en) | 2009-10-02 | 2016-07-19 | The National Veterinary Institute | Piscine reovirus immunogenic compositions |
| CN103347535B (zh) | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | 液体病毒制剂 |
| EP2646052B1 (en) | 2010-12-02 | 2017-03-29 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| SG194449A1 (en) * | 2011-04-29 | 2013-12-30 | Oncolytics Biotech Inc | Methods of purifying viruses using gel permeation chromatography |
| ES2796950T3 (es) * | 2013-11-15 | 2020-11-30 | Oncolytics Biotech Inc | Virus oncolíticos y regímenes reforzados para tratamiento de cáncer |
| US9660989B1 (en) | 2014-01-31 | 2017-05-23 | Google Inc. | Internet-wide identity management widget |
| WO2017141942A1 (ja) | 2016-02-16 | 2017-08-24 | 国立大学法人大阪大学 | 線維化を治療するための医薬組成物 |
| WO2019237063A1 (en) * | 2018-06-07 | 2019-12-12 | Emory University | Modified reoviruses, particles, and uses in treating proliferative disorders |
| KR102401077B1 (ko) | 2019-01-25 | 2022-05-24 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020227245A1 (en) * | 2019-05-03 | 2020-11-12 | Kansas State University Research Foundation | Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs |
| JP2024500164A (ja) * | 2020-12-22 | 2024-01-04 | バイロキュア インコーポレイテッド | 新規な改変レオウイルス及びその用途 |
| KR20220090467A (ko) * | 2020-12-22 | 2022-06-29 | 바이로큐어 주식회사 | 신규한 변형 레오바이러스 및 이의 용도 |
| US20250154204A1 (en) * | 2021-09-24 | 2025-05-15 | Virocure, Inc. | Novel reovirus-based vaccine platform and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| ES2347523T3 (es) | 2000-11-09 | 2010-11-02 | Oncolytics Biotech, Inc. | Metodos para el tratamiento de trastornos proliferativos celulares. |
| AU2002220416A1 (en) | 2000-12-01 | 2002-06-11 | University Of Ottawa | Oncolytic virus |
| CA2437962C (en) | 2001-03-16 | 2005-11-15 | Oncolytics Biotech Inc. | Method of extracting virus from cell culture |
| US7163678B2 (en) | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| AU2005257107A1 (en) | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having RNA virus transferred thereinto |
| EP1917351A4 (en) * | 2005-08-01 | 2009-12-16 | Univ Technologies Int | ATTENUATED REOVIRUS |
| WO2008009115A1 (en) | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
| EP2132315B1 (en) | 2007-03-12 | 2015-07-15 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
| JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
| EP2646052B1 (en) * | 2010-12-02 | 2017-03-29 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| CN103347535B (zh) * | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | 液体病毒制剂 |
-
2008
- 2008-03-11 EP EP08733587.3A patent/EP2132315B1/en active Active
- 2008-03-11 ES ES08733587.3T patent/ES2548442T3/es active Active
- 2008-03-11 CA CA2678721A patent/CA2678721C/en active Active
- 2008-03-11 MX MX2009009598A patent/MX2009009598A/es active IP Right Grant
- 2008-03-11 DK DK08733587.3T patent/DK2132315T3/en active
- 2008-03-11 EP EP15176066.7A patent/EP2952583A1/en not_active Withdrawn
- 2008-03-11 WO PCT/CA2008/000483 patent/WO2008110004A1/en not_active Ceased
- 2008-03-11 US US12/046,095 patent/US7803385B2/en active Active
- 2008-03-11 CN CN201310353609.2A patent/CN103710359A/zh active Pending
- 2008-03-11 KR KR1020097019418A patent/KR101647843B1/ko active Active
- 2008-03-11 SG SG2013040027A patent/SG191602A1/en unknown
- 2008-03-11 JP JP2009552983A patent/JP5577103B2/ja active Active
- 2008-03-12 TW TW097108636A patent/TW200904979A/zh unknown
- 2008-03-12 AR ARP080101017A patent/AR066395A1/es unknown
- 2008-03-14 AU AU2008226291A patent/AU2008226291B2/en active Active
-
2009
- 2009-08-12 IL IL200353A patent/IL200353A/en active IP Right Grant
- 2009-08-27 ZA ZA2009/05951A patent/ZA200905951B/en unknown
- 2009-09-08 MX MX2013013938A patent/MX346950B/es unknown
-
2010
- 2010-08-02 US US12/848,684 patent/US8691241B2/en active Active
-
2012
- 2012-08-30 IL IL221702A patent/IL221702A0/en unknown
- 2012-08-30 IL IL221701A patent/IL221701A0/en unknown
- 2012-08-30 IL IL221700A patent/IL221700A0/en unknown
-
2014
- 2014-02-13 US US14/179,840 patent/US10039827B2/en active Active
-
2018
- 2018-07-03 US US16/027,206 patent/US10596260B2/en active Active
-
2020
- 2020-02-13 US US16/790,114 patent/US11246930B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520758A5 (cg-RX-API-DMAC7.html) | ||
| JP5577103B2 (ja) | 改変配列を有するレオウイルス | |
| AU782020B2 (en) | Viruses for the treatment of cellular proliferative disorders | |
| CN102858959B (zh) | 溶瘤弹状病毒 | |
| JP7564572B2 (ja) | 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット | |
| Bourke et al. | The emerging role of viruses in the treatment of solid tumours | |
| Sinkovics et al. | Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers | |
| CA2494844A1 (en) | Methods and compositions concerning poxviruses and cancer | |
| JP7239910B2 (ja) | 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| WO2018058258A1 (en) | Recombinant oncolytic viruses for cancer therapy | |
| CN101679953A (zh) | 突变的呼肠孤病毒及其制备和使用方法 | |
| JP7144915B2 (ja) | 腫瘍を治療するためのウイルス | |
| CN119709652A (zh) | 溶瘤病毒及其应用 | |
| AU2014292114B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| CN101137391B (zh) | 重组高效复合干扰素的用途 | |
| JP7336791B2 (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| WO2024207908A1 (zh) | 减毒西尼罗河病毒的疫苗、药物及应用 | |
| US20220296659A1 (en) | Pharmaceutical composition for treatment of tumor or cancer, and application thereof | |
| WO2020238427A1 (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
| AU2009253683B2 (en) | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| WO2019174610A1 (zh) | 一种溶瘤病毒、合成dna序列及其应用 | |
| WO2022245808A1 (en) | Oncolytic virus based cancer therapy | |
| CN120789239A (zh) | 重组溶瘤病毒和单克隆抗体联用在制备用于治疗hbv阳性肝癌的药物中的应用 | |
| Popov | Literature Overview. |